Clinical trials: Over Cancer
Breast Cancer
Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65
This study will examine the outcomes of lumpectomy, surgery to remove a tumor, without sentinel node biopsy (SNB) for women at least 65 years of age with clinically node-negative breast cancer.
- Trial name
- NCT02564848
- Testing
- Lumpectomy without sentinel node biopsy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Cedars-Sinai Medical Center
Pain, Pediatric ALL
Validation of the ANI in Perpubescent Patients in Pediatric Intensive Care Unit.
The ANI monitor is a medical device allowing to measure the response of the autonomic nervous system to a painful stimulus. In the pediatric population under general anesthesia, the ANI score can detect failure of locoregional…
- Trial name
- ANI-EP (NCT04913038)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Lille
Mild Cognitive Impairment, Dementia, Mild
Effects of Multimodal Cognitive Enhancement Therapy (MCET) for Ealy Dementia
This study evaluates the effects of Multimodal Cognitive Enhancement Therapy (MCET) for people with mild cognitive impairment and early stage dementia by a randomized, controlled (mock-therapy), double-blind, cross-over trial
- Trial name
- NCT02350738
- Testing
- Period I MCET (8 wks), Washout (4 wks), Period II MCET (8 wks)
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Ki Woong Kim
Hodgkin Lymphoma, Adult
Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy
Outcome of Hodgkin lymphoma patients over than 60 years treated by chemotherapy and/or radiotherapy: retrospective analysis.
- Trial name
- HODGSA (NCT03535948)
- Where
- 2 sites in France
- Volunteers
- 90 people
- Sponsor
- Central Hospital, Nancy, France
Tuberous Sclerosis Complex
Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC
The study intends to show that basimglurant (NOE-101) provides effective seizure control in children, adolescents and young adults with Tuberous Sclerosis Complex (TSC).
- Trial name
- NCT05059327
- Where
- 27 sites in United States, India and 6 more
- Volunteers
- 61 people
- Sponsor
- Noema Pharma AG
Chronic Pain, Insomnia
The Efficacy of CALPXT96™in Improving Sleep Quality in Patients With Chronic Non-cancer Pain
California Poppy has been traditionally used in Herbal Medicine as an analgesic, mild sedative and/or sleep aid. However there are no human clinical trial data to support its use.
- Trial name
- CALPXT96 (NCT02232256)
- Testing
- CALPXT96
- Where
- Canada
- Sponsor
- 9305-9954 Quebec Inc
Colorectal Tumor
ANC1 Study Impact of a Geriatric and Nutritional Evaluation for the Malnutrition and Malnutrition Risk Screening in Patients Over 70 Years With Colorectal Surgery.
Malnutrition priori a major abdominal surgery is frequent and increases morbidity and mortality. The management of malnutrition has an impact in reducing postoperative complications.
- Trial name
- ANC1 (NCT02084524)
- Testing
- Malnutrition screening and perioperative nutritional support
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Hospices Civils de Lyon
Opioid-Refractory Chronic Cancer-Related Pain
The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.
This is a randomized, double-blinded, placebo-controlled, cross-over trial examining the effect of a series of two weekly intravenous infusions of lidocaine 4 mg/kg and ketamine 0.2 mg/kg in patients with moderate to severe…
- Trial name
- NCT07408193
- Testing
- Lidocaine and Ketamine Infusion
- Where
- Greece
- Volunteers
- 24 people
- Sponsor
- National and Kapodistrian University of Athens
Hepatocellular Carcinoma
Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH
The aim of this study is to explore the effect of Transarterial Chemoembolization (TACE) on the prognosis of patients with microvascular invasion presence(MVI) and overexpression of Aspartate-β-hydroxylase(ASPH).
- Trial name
- NCT02587884
- Testing
- TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Invasive Fungal Infection, Hematological Malignancy
Pharmacologic Optimization of Voriconazole
The objective of this study proposal is to determine whether pharmacologic optimization of voriconazole by means of therapeutic drug monitoring (TDM) results in improved patient outcomes (efficacy and safety) and is more…
- Trial name
- VORI911 (NCT00893555)
- Testing
- voriconazole, voriconazole (dosing according to the SPC)
- Where
- Netherlands
- Volunteers
- 189 people
- Sponsor
- Jan-Willem C Alffenaar
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial
This phase II trial tests how well fezolinetant works in improving vasomotor symptoms (VMS) in breast cancer patients taking endocrine therapy (ET).
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ
- Trial name
- VEnT (NCT06617455)
- Testing
- Biospecimen Collection, Fezolinetant, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Michigan Rogel Cancer Center
Leiomyoma
Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670
Effects of BAY1002670 on bleeding pattern: non-bleeding rate; on endometrium; on ovarian function; return of menstrual bleeding after treatment; safety and tolerability; PK/PD (pharmacokinetic/pharmacodynamic) relationship
- Trial name
- NCT01816815
- Testing
- BAY1002670
- Where
- 6 sites in Belgium, Germany and 1 more
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Bayer
Breast Cancer
Impact of Cognitive Impairment on Chronic Pain in Breast Cancer
Breast cancer treatments are associated with frequent and sometimes severe adverse effects that may significantly impair quality of life and lead to functional disability.
- Trial name
- Cactus (NCT07877376)
- Testing
- Evaluation of cognitive functions in patients with beast cancer
- Where
- France
- Volunteers
- 182 people
- Sponsor
- Nadine ATTAL
Metastatic Colorectal Cancer
Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer
This is a multicentric, phase II and open label study.75 patients are expected to be randomized in 35 centers. The main objective is to assess the efficacy and safety of Afatinib -cetuximab combo versus cetuximab alone in…
- Trial name
- NCT01919879
- Testing
- Cetuximab + Afatinib, Cetuximab
- Where
- France
- Volunteers
- 75 people
- Sponsor
- UNICANCER
Breast Cancer
Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00943410
- Testing
- external beam radiation therapy, Herceptin
- Volunteers
- 19 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Tumors
A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
This is a Phase 1, open-label, randomized, 2-sequence, cross-over, pharmacokinetic (PK) study evaluating the effect of the DPD inhibitory action of CDHP as an S-1 component compared with FT alone on the PK of 5-FU in patients…
- Trial name
- NCT00400023
- Testing
- S-1, FT
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Taiho Oncology, Inc.
Hearing Loss, Bilateral Sensorineural, Progressive, Hearing Loss, Bilateral (Causes Other Than Tumors)
Hearing Screening in Adults Over 50 Years Old
The goal of this single-arm quasi-experimental study is to evaluate the feasibility, effectiveness, and management of three different hearing screening methods in adults aged 50 years and older in the Czech Republic.
- Conditions
- Hearing Loss, Bilateral Sensorineural, Progressive, Hearing Loss, Bilateral (Causes Other Than Tumors), Hearing Loss, Bilateral or Unilateral, Presbyacusis
- Trial name
- HSA50+ (NCT06894927)
- Testing
- Screening HHIA questionnaire, Whispered voice test, Screening pure tone audiometry
- Where
- 2 sites in Czechia
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- University Hospital Hradec Kralove
Multiple Myeloma, Breast Cancer
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
The primary objective of this study is to investigate the repeat-dose pharmacokinetic (PK) profile of zoledronic acid when administered every 4 weeks versus every 12 weeks, in patients treated with 9-20 infusions of zoledronic…
- Trial name
- NCT00424983
- Testing
- Zoledronic acid
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Malignant
Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim
Observation of a cohort of 400 patients with different types of lymphomas.
- Trial name
- DVR-Lym-Nim (NCT04947618)
- Where
- France
- Volunteers
- 136 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Acute Promyelocytic Leukemia (APL)
Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
Randomized, Open-Label Study to evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) under Fasting and Fed Conditions, to Compare to IV Arsenic Trioxide
- Trial name
- NCT06882031
- Testing
- Treatment A: Arsenic Trioxide (ATO) Intravenous, Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state, Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state
- Where
- Hong Kong
- Volunteers
- 12 people
- Sponsor
- SDK Therapeutics, Inc.